CLEVELAND BIOLABS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cleveland BioLabs, Inc. - CBLI

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Monday, October 26, 2020
Information
Tags: 
Legal, Professional services, Charles Foti, Foti, Cleveland BioLabs, New Orleans, LOUISIANA
Geotags: 
United States, LOUISIANA
⚠generated by AI ↴
Summary
Key Points: 
  • Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
  • and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed merger of Cleveland BioLabs, Inc. (NasdaqGS: CBLI) with Cytocom, Inc. pursuant to which Cleveland BioLabs shareholders will end up owning just 39% of the combined company.
  • KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .


Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Cleveland BioLabs, Inc. (NasdaqGS: CBLI) with Cytocom, Inc. pursuant to which Cleveland BioLabs shareholders will end up owning just 39% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ([email protected]) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-cbli/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

Copyright: 
Copyright Business Wire 2020